PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Historical Holders from Q3 2020 to Q3 2025

Symbol
PMVP on Nasdaq
Type / Class
Equity / Common stock, par value $0.00001 per share
Shares outstanding
52.9M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
37.5M
Holdings value
$52.5M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
63
Number of buys
31
Number of sells
-27
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 9.4% $6.97M 4.98M ORBIMED ADVISORS LLC 23 Oct 2025
TANG CAPITAL MANAGEMENT LLC 8.9% $6.7M 4.72M TANG CAPITAL MANAGEMENT, LLC 16 Sep 2025
BML Investment Partners, L.P. 6.7% $3.74M 3.47M BML Investment Partners, L.P. 31 Dec 2024
Sio Capital Management, LLC 4.98% -31.6% $3.69M -$1.54M 2.64M -29.4% Sio Capital Management, LLC 30 Sep 2025

Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 37.5M $52.5M +$4.77M $1.40 63
2025 Q2 34.7M $36.8M -$2.91M $1.06 52
2025 Q1 37.3M $40.7M -$2.28M $1.09 54
2024 Q4 39M $58.8M -$768K $1.51 70
2024 Q3 39M $58.2M -$2.42M $1.49 73
2024 Q2 40.5M $65.6M -$3.77M $1.62 91
2024 Q1 42.7M $72.6M -$11.9M $1.70 96
2023 Q4 46.5M $144M -$52.2M $3.10 97
2023 Q3 54.2M $333M +$15.4M $6.14 103
2023 Q2 51.7M $324M +$3.28M $6.26 104
2023 Q1 51.5M $246M -$16.2M $4.77 111
2022 Q4 54.6M $475M -$38.3M $8.70 113
2022 Q3 58.2M $692M -$36.6M $11.90 116
2022 Q2 61.1M $871M +$53.5M $14.25 105
2022 Q1 55.2M $1.15B +$162M $20.82 98
2021 Q4 47.5M $1.1B +$15.2M $23.10 102
2021 Q3 44M $1.31B +$46.8M $29.80 91
2021 Q2 42.2M $1.44B +$80M $34.16 83
2021 Q1 39.9M $1.31B +$51.9M $32.89 81
2020 Q4 38.2M $2.34B +$185M $61.51 72
2020 Q3 31.2M $1.1B +$1.1B $35.50 51